Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma
In: Cancer Chemotherapy and Pharmacology, Jg. 83 (2019-01-08), S. 581-587
Online
unknown
Zugriff:
To further improve the prognosis of esophageal cancer patients, it is necessary to investigate new treatment strategies. The purposes of this study were to retrospectively assess the safety and efficacy of neoadjuvant chemoradiotherapy (CRT) with docetaxel/cisplatin/5-fluorouracil (DCF) (DCF-RT) in patients with thoracic esophageal squamous cell carcinoma (ESCC). We reviewed 30 thoracic ESCC patients who underwent neoadjuvant DCF-RT followed by esophagectomy, and evaluated the safety and efficacy of DCF-RT. DCF-RT consisted of 40 Gy radiation with two courses of intravenous DCF (docetaxel, 30 mg/m2/day, day 1; cisplatin, 7 mg/m2/day, day 1; 5-FU, 350 mg/m2/day, days 1–5 and days 8–12) repeated every 2 weeks. Esophagectomy was scheduled 8–10 weeks after completion of DCF-RT. Twenty-nine of thirty patients completed radiotherapy; however, 27 of 30 patients required dose reduction of the second cycle of DCF. Complete response (CR), partial response, and stable disease were observed in 7, 11, and 10 patients, respectively. The number of lymph node metastases after DCF-RT was significantly lower than that before DCF-RT (P
Titel: |
Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma
|
---|---|
Autor/in / Beteiligte Person: | Maemura, Kosei ; Osako, Yusaku ; Natsugoe, Shoji ; Okumura, Hiroshi ; Higashi, Ryutaro ; Omoto, Itaru ; Noda, Masahiro ; Uchikado, Yasuto ; Sasaki, Ken ; Yoshiura, Takashi ; Arigami, Takaaki |
Link: | |
Zeitschrift: | Cancer Chemotherapy and Pharmacology, Jg. 83 (2019-01-08), S. 581-587 |
Veröffentlichung: | Springer Science and Business Media LLC, 2019 |
Medientyp: | unknown |
ISSN: | 1432-0843 (print) ; 0344-5704 (print) |
DOI: | 10.1007/s00280-018-03764-4 |
Schlagwort: |
|
Sonstiges: |
|